| Document |
Document Title |
|
WO/2005/111026A1 |
A method of synthesising compounds of formula (I), wherein R1 and R2, which are the same or different, are each a branched or linear (C1-C8) alkoxy grouping or together form, with the carbon atom bearing them, a 1,3-dioxane, 1,3-dioxolan...
|
|
WO/2005/110984A1 |
A cyclic polycarboxylic anhydride, a polycarboxylic acid, or a mixture of these is reacted with hydroxylamine or a salt thereof in an organic solvent under dehydrating conditions to obtain the corresponding cyclic N-hydroxyimide compound...
|
|
WO/2005/108368A1 |
The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzy...
|
|
WO2005030794B1 |
The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of cancer, wherein R1-R7, X1, X2, R, Q, and n are as defined herein.
|
|
WO/2005/097778A1 |
The present invention relates to novel benzazepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.
|
|
WO/2005/097738A1 |
Disclosed are a compound represented by the formula (1) below, a prodrug thereof, and their pharmaceutically acceptable salts which have an effect of increasing LDL receptor expression and are useful as drugs for treating hyperlipemia, a...
|
|
WO/2005/096709A2 |
A process for preparing 10,11-dihydro-10-oxo-5H-dibenz[b,f]azepine-5- carboxamide, compound of formula (I), said process comprising a. reacting compound of of formula (Ivb) with alkali metal methoxide to yield compound of formula (II); a...
|
|
WO/2005/094835A1 |
Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.
|
|
WO/2005/094834A1 |
Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.
|
|
WO/2005/095338A1 |
The invention aims at providing novel compounds having regulatory effect on the activity of GPR (G protein-coupled receptor) 40 and being useful as insulin secretagogue or preventive or therapeutic agent for diabetes and so on. Compounds...
|
|
WO/2005/092290A1 |
The invention relates to pharmaceutical compositions comprising 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide
(also referred to as “licarbazepine”) as drug substance.
|
|
WO/2005/092862A1 |
Process for preparing oxcarbazepine according to Scheme 1: characterized by the use of triphosgene as chlorocarbonylating agent in step a).
|
|
WO/2005/087746A1 |
The present invention relates to novel benzazepine derivatives of formula (I); wherein: R1 represents -C3-7 cycloalkyl optionally substituted by C1-3 alkyl; R2 represents -aryl, -heterocyclyl, heteroaryl, -aryl-X-C3-8 cycloalkyl, -aryl-X...
|
|
WO/2005/085183A1 |
The invention relates to a method of preparing benzazepine compounds having general formula (IA) consisting in reacting at least one compound having general formula (IIA) with an olefin, the compound thus obtained then being cyclised suc...
|
|
WO/2005/082859A1 |
The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, dep...
|
|
WO/2005/077907A1 |
The invention concerns novel tetrahydrobenzo[d]azepin-2-one derivatives, a method for the production thereof, their use for treating and/or preventing diseases, and their use for producing medicaments for treating and/or preventing disea...
|
|
WO/2005/077908A1 |
A guanidine compound which has a bi-aryl skeleton represented by the following general formula (1): [wherein R1, R2 and R3 each independently represents a hydrogen atom, a hydrocarbon group optionally having a substituent or a heterocycl...
|
|
WO/2005/077921A1 |
A guanidine compound which has a bi-aryl skeleton represented by the following general formula (1): [wherein R1, R2 and R3 each independently represents a hydrogen atom, a hydrocarbon group optionally having a substituent or a heterocycl...
|
|
WO/2005/073196A1 |
A compound of the following formula (I). This compound (I) can be produced by reacting a 1,1'-binaphthyl 2,2'-dimethylenebromide derivative which can be produced through a relatively small number of steps with an easily available seconda...
|
|
WO/2005/070877A1 |
The application relates to novel amino alcohols of the general formula (I) where R, R1, R2, R3, R4, R5 and R6 each have the definitions illustrated in detail in the description, to a process for their preparation, and to the use of these...
|
|
WO/2005/070887A1 |
A compound of the general formula (I) including its pharmaceutically acceptable acid addition salts formula (I) wherein A is CHR9, wherein R9 is H, C1-C6 alkyl;n is 1-3; B is CHR10, wherein R10 is H, C1-C6 alkyl; m is 1 or 2; D is O or S...
|
|
WO/2005/068643A2 |
The invention relates to biochemical synthesis of 6-amino caproic acid from 6-aminohex-2-enoic acid compound or from 6-amino-2-hydroxyhexanoic acid, by treatment with an enzyme having &agr ,β-enoate reductase activity towards molecules ...
|
|
WO/2005/066159A1 |
The present invention relates to a novel class of compounds mainly, leucinamide-amino-carboxylate derivatives of formula (I) wherein Y is CR1R2, O, S, -SO2, C=0 or NR9; Z is CR1R2, O, S, -SO2, C=O or NR9 and each G is independently a CR1...
|
|
WO/2005/066123A1 |
This invention relates to treating an infection with a virus using protease inhibitors. Examples of the protease inhibitors include compounds of formula (I). Each variable is defined in the specification.
|
|
WO/2005/066133A2 |
Novel process for preparation of 10-oxo-10, 11-dihydro-SH-dibenz[b,f] azepine-5-carboxamide (oxcarbazepine) via intermediate 10-methoxy-5H-dibenz [b,f] azepine -5 carbonyl, chloride; comprising the steps: a) Preparation of an interme...
|
|
WO/2005/066134A1 |
Dicarboxylic acid salts of compounds of the formula (II) wherein R represents a selectively removable protecting group; and (S) denotes the (S)-configuration of the asymmetric carbon atoms, which are useful as intermediates for the prepa...
|
|
WO/2005/058837A1 |
The present invention relates to novel benzazepine derivatives of structure (I) having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psych...
|
|
WO/2005/058328A1 |
The invention relates to tetrahydrobenzazepines of the general formula (I) in which the variables Ar, A, B, Y, R1 and R2 have the meanings indicated in claim 1, as well as the N-oxides of these compounds, the physiologically tolerated ac...
|
|
WO/2005/056546A1 |
The invention relates to novel keto lactam compounds, hydrogenated derivatives and tautomers thereof. These compounds have valuable therapeutic properties and are particularly suited for treating diseases that respond to the modulation o...
|
|
WO/2005/053702A2 |
The invention relates to the use of 3-aminocaprolactam derivatives for preparing a medicament intended to prevent or treat inflammatory disorders, and uses compounds of general formula (I) or a pharmaceutically acceptable salts thereof; ...
|
|
WO/2005/054190A1 |
This invention is related to compounds and use of 3-aminopyrrolidone derivatives and analogues of the following general formula (I), wherein m is an integer from 1 to 3; X is methylene, oxygen, sulphur or a NR6 group; R1 is a straight or...
|
|
WO/2005/051916A1 |
The present invention relates to novel salts of 7-[4-(4-chlorobenzyloxy)benzenesulfonyl]-8-methoxy-3-methyl-
2,3,4,5-tetrahydro-1H-3-benzazepine and a pharmaceutically acceptable solvate thereof, pharmaceutical formulations, processes fo...
|
|
WO/2005/051399A1 |
This invention provides one or more chemical entities selected from a compound of formula (I) and a pharmaceutically acceptable salt and solvate thereof. The compounds of formula (I) and pharmaceutically acceptable salts or solvates ther...
|
|
WO/2005/051397A1 |
The invention provides one or more chemical entities selected from a compound of formula (I): (I) wherein R1 represents C1-6alkyl, trifluoromethoxy or halo; R2 represents hydrogen, C1-6alkyl or halo; or when R1 and R2 are positioned at t...
|
|
WO/2005/051398A1 |
The invention provides one or more chemical entities selected from a compound of formula (I): wherein R1 represents C1-6alkyl, C1-6alkoxy, trifluoromethyl, trifluoromethoxy, halo, cyano, 5-methyl-1,2,4-oxadiazol-3-yl or a group -SO2X; R2...
|
|
WO/2005/047182A1 |
Disclosed are a high silica zeolite having a novel crystal structure, a zeolite membrane and methods for producing them. The zeolite is represented by the chemical composition:[(Si36-xTy·O72)·Mz] (wherein M represents a cation of an al...
|
|
WO/2005/044803A1 |
The invention relates to bengamide derivatives which are formed by the micro-organism Myxococcus virescens ST200611 (DSM 15898), during fermentation, to the use thereof for the treatment of cancer, to medicaments containing bengamide der...
|
|
WO/2005/042489A1 |
Disclosed are N-substituted benzenesulfonamides for use intreating in treating or preventing cognitive disorders, such as Alzheimer´s Disease. Formula (I) In formula (I), R1, R2, R3, R4, R3’, R10 and R11 are described herein. The inve...
|
|
WO/2005/042491A1 |
The present invention relates to substituted-2,3,4,5-tetrahydro-3-benzazepine derivatives that are modulators of the 5HT2C receptor. Accordingly, compounds of the present invention are useful for the prophylaxis or treatment of 5HT2C rec...
|
|
WO/2005/042490A1 |
The present invention relates to substituted-2,3,4,5-tetrahydro-3-benzazepine derivatives that are modulators of the 5HT2C receptor. Accordingly, compounds of the present invention are useful for the prophylaxis treatment of 5HT2C recept...
|
|
WO/2005/042697A2 |
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.
|
|
WO/2005/040108A1 |
This invention is related to novel prolinamide derivatives and analogues of general formula (I) wherein Q is C3-C8 alkyl, or C1-C8 alkyl substituted by phenoxy or saturated or unsaturated 5 to 7 membered ring optionally containing one or...
|
|
WO/2005/039591A1 |
The present invention relates to novel benzazepine derivatives of the following formula: (I) wherein R1, R2, R3, R4 and R5, X, X’, Y and Y’ are as defined in the description and claims, processes for their preparation, pharmaceutical...
|
|
WO/2005/040126A1 |
The present invention relates to compounds of the general formula (I) Wherein R1 is -(CHR’)q-aryl or -(CHR')q-heteroaryl, which are unsubstituted or mono, di- or tri-substituted by lower alkyl, lower alkoxy, CF3 or halogen, or is lower...
|
|
WO/2005/037269A1 |
A compound represented by the following formula (1), a prodrug thereof, or a pharmaceutically acceptable salt of either. They are effective in enhancing LDL receptor manifestation and are useful as a therapeutic agent for hyperlipemia, a...
|
|
WO/2005/037796A1 |
Compounds of formula I wherein n, m, p, q, Y, R1 R2, R3, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating artherosclerosis and its sequelae.
|
|
WO/2005/037785A2 |
The invention relates to compounds having general formula (I), wherein: n represents the number 1 or 3; R1 represents either H or a cycloalkyl, cycloalkylalkyl, phenylalkyl, alkenyl, alkynyl group; X represents either H or one or more su...
|
|
WO/2005/037795A2 |
The invention is directed to nonpeptide substituted benzazepines of Formula (I), which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased...
|
|
WO/2005/035504A2 |
The present invention provides compounds of formula (I), which, are novel antagonists for D1/D5 receptors as well as methods for preparing such compounds. In another embodiment, the invention provides pharmaceutical compositions comprisi...
|
|
WO/2005/030730A1 |
An industrially advantageous production process which is an improved process for the production of an optically active &agr -amino-&epsiv -caprolactam (ACL). By the process, a desired optically active isomer having a high optical purity ...
|
